DateTechnology PlatformDownloadTitle
June 5, 2016Orascovery PlatformpdfAn open label, randomised cross-over bioavailability study of Oral Paclitaxel (Oraxol) compared to intravenous paclitaxel 80mg/m.

Poster presented at: American Society of Clinical Oncology Annual Meeting; Chicago, IL.
November 17-19, 2017Orascovery PlatformpdfAn open label, randomised cross-over bioavailability and extension study of oral paclitaxel and HM30181 (Oraxol) compared to weekly intravenous paclitaxel 80mg/m2 in advanced solid tumours.

Poster presented at: European Society for Medical Oncology Asia; Singapore.
April 4, 2018Src Kinase InhibitiondownloadDiscovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).

Published by: Journal of Medicinal Chemistry
June 1-5, 2018Orascovery PlatformpdfAn open label, randomised cross-over bioavailability and extension study of Oral Paclitaxel and HM30181 (Oraxol) compared to weekly intravenous paclitaxel 80 mg/m2 in advanced solid tumours.

Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL.
June 4, 2018Orascovery PlatformpdfA phase I study to evaluate safety, tolerability, pharmacokinetics and activity of Oraxol in patients with advanced malignancies.

Poster presented at: American Society of Clinical Oncology Annual Meeting; Chicago, IL.
March 29-April 3, 2019Orascovery PlatformpdfEffective preclinical management of angiosarcoma with oral paclitaxel.

Poster presented at: the American Association for Cancer Research (AACR) Annual Meeting; Atlanta, GA.
May 31-June 4, 2019Arginine Deprivation TherapypdfDesign, engineering, and characterization of a novel long-acting (pegylated) single isomer human arginase for arginine-depriving anti-cancer treatment.

Poster presented at: American Society of Clinical Oncology; Chicago, IL.
May 31-June 4, 2019Orascovery Platformpdf1084- Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients.

Poster presented at: American Society of Clinical Oncology; Chicago, IL.
May 31-June 4, 2019Orascovery PlatformpdfA phase 1 study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor encequidar (NTC02250157).

Poster presented at: American Society of Clinical Oncology; Chicago, IL.
May 31-June 4, 2019Orascovery PlatformpdfAn open label, randomized, multicenter, phase 3 registrational study to determine the safety, tolerability, and tumor response of oral paclitaxel and encequidar (formerly HM30181A) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC) (NCT-02594371).

Poster presented at: American Society of Clinical Oncology; Chicago, IL.
September 27-October 1, 2019Orascovery PlatformpdfA Phase 1b Study of Oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.

Poster presented at: European Society for Medical Oncology (ESMO) Congress; Barcelona, Spain.
September 27-October 1, 2019Orascovery PlatformpdfA pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010).

Poster presented at: European Society for Medical Oncology (ESMO) Congress; Barcelona, Spain.
September 27-October 1, 2019Orascovery PlatformpdfAn international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 (Oraxol) compared with weekly intravenous (IV) paclitaxel 80mg/m2 in advanced solid tumors.

Poster presented at: European Society for Medical Oncology (ESMO) Congress; Barcelona, Spain.
May 29-31, 2020Orascovery PlatformpdfA Phase II Study of Oral Paclitaxel with Encequidar in the Treatment of Unresectable Cutaneous Angiosarcoma.

Poster presented at: American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program.
October 19-23, 2018Orascovery PlatformpdfAn open label, single-arm pharmacokinetic study of oral paclitaxel and HM30181 in metastatic breast cancer patients

Poster presented at: European Society for Medical Oncology (ESMO) Congress; Munich, Germany.
December 10-14, 2019Orascovery PlatformpdfOral paclitaxel with encequidar (OPE): The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: A Phase III clinical study in metastatic breast cancer

Oral presentation at: San Antonio Breast Cancer Symposium; Texas.
February 17, 2018Src Kinase InhibitionpdfPhase II Study of KX2-391 Ointment 1%, a Novel Field Treatment Based on Src/Tubulin Polymerization Inhibition, for Actinic Keratosis

Oral Presentation at: American Academy of Dermatology Annual Meeting; San Diego, California.
March 2, 2019Src Kinase InhibitionpdfKX2-391 Ointment 1%, a Novel Dual Src/Tubulin Inhibitor, is Efficacious and Safe in the Treatment of Adults with Actinic Keratosis in Two Pivotal Phase III Studies

Oral Presentation at: American Academy of Dermatology Annual Meeting; Washington, DC.